X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-positive-phase-3-response-data-of-cymabays-seladelpar-in-primary-biliary-cholangitis-302068089.html
https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics
https://www.prnewswire.com/news-releases/cymabay-announces-fda-acceptance-of-nda-and-priority-review-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis-302059522.html
https://www.prnewswire.com/news-releases/new-published-data-demonstrates-correlation-between-itch-cytokine-interleukin-31-reduction-and-pruritis-improvement-in-primary-biliary-cholangitis-in-phase-3-post-hoc-analysis-of-cymabays-seladelpar-302024982.html
https://www.prnewswire.com/news-releases/cymabay-submits-new-drug-application-to-fda-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis-302016212.html
https://www.prnewswire.com/news-releases/cymabay-announces-an-oral-presentation-of-seladelpar-phase-3-pivotal-results-in-primary-biliary-cholangitis-at-the-late-breaker-session-of-the-liver-meeting-301985498.html
https://www.globenewswire.com//news-release/2023/11/01/2771113/37067/en/CymaBay-Announces-Publication-of-Two-year-Safety-and-Efficacy-Results-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis.html
https://www.globenewswire.com//news-release/2023/10/23/2764648/37067/en/Seladelpar-Granted-Revised-Breakthrough-Therapy-Designation-for-the-Treatment-of-Primary-Biliary-Cholangitis-Including-Pruritus-in-Patients-Without-Cirrhosis-or-With-Compensated-Ci.html
https://www.globenewswire.com//news-release/2023/10/18/2762280/37067/en/CymaBay-s-RESPONSE-Phase-3-Data-Evaluating-Seladelpar-for-Primary-Biliary-Cholangitis-to-be-Featured-in-an-Oral-Late-Breaking-Presentation-at-The-Liver-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/09/21/2747218/37067/en/CymaBay-Initiates-AFFIRM-a-Phase-3b-4-Study-Evaluating-the-Effect-of-Seladelpar-on-Clinical-Outcomes-in-Patients-with-Cirrhosis-due-to-Primary-Biliary-Cholangitis.html
https://www.prnewswire.com/news-releases/cymabays-seladelpar-achieves-high-statistical-significance-for-the-primary-and-key-secondary-endpoints-in-the-phase-3-response-trial-in-primary-biliary-cholangitis-301920135.html
https://www.prnewswire.com/news-releases/cymabay-initiates-ideal-a-phase-3-placebo-controlled-randomized-study-of-seladelpar-in-patients-with-primary-biliary-cholangitis-and-incomplete-control-of-alkaline-phosphatase-301897588.html
https://www.globenewswire.com/news-release/2023/04/21/2651878/37067/en/CymaBay-Therapeutics-Announces-Publication-of-Results-From-the-ENHANCE-Phase-3-Study-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis-PBC.html
https://www.globenewswire.com/news-release/2022/04/04/2415686/37067/en/CymaBay-Therapeutics-Announces-Publication-of-Results-From-a-52-Week-Open-Label-Phase-2-Study-of-Seladelpar-in-Patients-With-Primary-Biliary-Cholangitis.html
https://www.globenewswire.com/news-release/2022/02/03/2378836/0/en/Bon-Secours-Liver-Institute-of-Richmond-Participating-in-RESPONSE-a-Global-Phase-3-Clinical-Research-Study-Evaluating-an-Investigational-Therapy-for-the-Treatment-of-Primary-Biliar.html
https://www.globenewswire.com/news-release/2022/02/01/2376714/0/en/Liver-Institute-Northwest-Participating-in-RESPONSE-a-Global-Phase-3-Clinical-Research-Study-Evaluating-an-Investigational-Therapy-for-the-Treatment-of-Primary-Biliary-Cholangitis-.html
https://www.globenewswire.com/news-release/2021/06/09/2244337/37067/en/CymaBay-Therapeutics-Announces-Presentations-During-The-International-Liver-Congress-2021.html
https://www.globenewswire.com/news-release/2020/10/01/2102151/0/en/CymaBay-Therapeutics-to-Present-Data-from-its-Phase-2-Study-of-Seladelpar-in-Patients-with-NASH-at-The-Liver-Meeting-2020.html
https://endpts.com/fda-lifts-hold-on-cymabays-nash-drug-but-the-company-may-still-leave-the-ailing-field/
https://endpts.com/genfit-goes-to-china-with-a-deal-worth-up-to-228m-for-nash-drug/
https://endpts.com/nash-contender-cymabay-runs-into-trouble-as-mid-stage-data-disappoint/
https://globenewswire.com/news-release/2019/02/15/1726160/0/en/CymaBay-Therapeutics-Announces-Seladelpar-Granted-Breakthrough-Therapy-Designation-by-the-FDA-for-the-Treatment-of-Primary-Biliary-Cholangitis.html
Market Place
Share 
